Noll L Campbell1,2,3,4, Anthony J Perkins5,6, Sujuan Gao2,3,7, Todd C Skaar8, Lang Li9, Hugh C Hendrie2,3,10, Nicole Fowler2,3,8, Christopher M Callahan2,3,8, Malaz A Boustani2,3,5,8. 1. Department of Pharmacy Practice, Purdue University School of Pharmacy, West Lafayette, Indiana. 2. Indiana University Center for Aging Research, Indianapolis, Indiana. 3. Regenstrief Institute, Inc., Indianapolis, Indiana. 4. Eskenazi Health, Indianapolis, Indiana. 5. Center for Healthcare Innovation and Implementation Science, Indianapolis, Indiana. 6. Indiana Clinical and Translational Sciences Institute, Indianapolis, Indiana. 7. Department of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana. 8. Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana. 9. Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana. 10. Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana.
Abstract
BACKGROUND/ OBJECTIVES: Post-marketing comparative trials describe medication use patterns in diverse, real-world populations. Our objective was to determine if differences in rates of adherence and tolerability exist among new users to acetylcholinesterase inhibitors (AChEI's). DESIGN: Pragmatic randomized, open label comparative trial of AChEI's currently available in the United States. SETTING: Four memory care practices within four healthcare systems in the greater Indianapolis area. PARTICIPANTS: Eligibility criteria included older adults with a diagnosis of possible or probable Alzheimer's disease (AD) who were initiating treatment with an AChEI. Participants were required to have a caregiver to complete assessments, access to a telephone, and be able to understand English. Exclusion criteria consisted of a prior severe adverse event from AChEIs. INTERVENTION: Participants were randomized to one of three AChEIs in a 1:1:1 ratio and followed for 18 weeks. MEASUREMENTS: Caregiver-reported adherence, defined as taking or not taking study medication, and caregiver-reported adverse events, defined as the presence of an adverse event. RESULTS:196 participants were included with 74.0% female, 30.6% African Americans, and 72.9% who completed at least twelfth grade. Discontinuation rates after 18 weeks were 38.8% for donepezil, 53.0% for galantamine, and 58.7% for rivastigmine (P = .063) in the intent to treat analysis. Adverse events and cost explained 73.1% and 25.4% of discontinuation. No participants discontinued donepezil due to cost. Adverse events were reported by 81.2% of all participants; no between-group differences in total adverse events were statistically significant. CONCLUSIONS: This pragmatic comparative trial showed high rates of adverse events and cost-related non-adherence with AChEIs. Interventions improving adherence and persistence to AChEIs may improve AD management. TRIAL REGISTRATION: Clinicaltrials.gov: NCT01362686 (https://clinicaltrials.gov/ct2/show/NCT01362686).
RCT Entities:
BACKGROUND/ OBJECTIVES: Post-marketing comparative trials describe medication use patterns in diverse, real-world populations. Our objective was to determine if differences in rates of adherence and tolerability exist among new users to acetylcholinesterase inhibitors (AChEI's). DESIGN: Pragmatic randomized, open label comparative trial of AChEI's currently available in the United States. SETTING: Four memory care practices within four healthcare systems in the greater Indianapolis area. PARTICIPANTS: Eligibility criteria included older adults with a diagnosis of possible or probable Alzheimer's disease (AD) who were initiating treatment with an AChEI. Participants were required to have a caregiver to complete assessments, access to a telephone, and be able to understand English. Exclusion criteria consisted of a prior severe adverse event from AChEIs. INTERVENTION: Participants were randomized to one of three AChEIs in a 1:1:1 ratio and followed for 18 weeks. MEASUREMENTS: Caregiver-reported adherence, defined as taking or not taking study medication, and caregiver-reported adverse events, defined as the presence of an adverse event. RESULTS: 196 participants were included with 74.0% female, 30.6% African Americans, and 72.9% who completed at least twelfth grade. Discontinuation rates after 18 weeks were 38.8% for donepezil, 53.0% for galantamine, and 58.7% for rivastigmine (P = .063) in the intent to treat analysis. Adverse events and cost explained 73.1% and 25.4% of discontinuation. No participants discontinued donepezil due to cost. Adverse events were reported by 81.2% of all participants; no between-group differences in total adverse events were statistically significant. CONCLUSIONS: This pragmatic comparative trial showed high rates of adverse events and cost-related non-adherence with AChEIs. Interventions improving adherence and persistence to AChEIs may improve AD management. TRIAL REGISTRATION: Clinicaltrials.gov: NCT01362686 (https://clinicaltrials.gov/ct2/show/NCT01362686).
Authors: D G Wilkinson; A P Passmore; R Bullock; S W Hopker; R Smith; F C V Potocnik; C M Maud; I Engelbrecht; C Hock; J R Ieni; R S Bahra Journal: Int J Clin Pract Date: 2002 Jul-Aug Impact factor: 2.503
Authors: Malaz Boustani; Christopher M Callahan; Frederick W Unverzagt; Mary G Austrom; Anthony J Perkins; Bridget A Fultz; Siu L Hui; Hugh C Hendrie Journal: J Gen Intern Med Date: 2005-07 Impact factor: 5.128
Authors: S López-Pousa; A Turon-Estrada; J Garre-Olmo; I Pericot-Nierga; M Lozano-Gallego; M Vilalta-Franch; M Hernández-Ferràndiz; V Morante-Muñoz; A Isern-Vila; E Gelada-Batlle; J Majó-Llopart Journal: Dement Geriatr Cogn Disord Date: 2005-01-25 Impact factor: 2.959
Authors: Anthony J Perkins; Kurt Kroenke; Jürgen Unützer; Wayne Katon; John W Williams; Carol Hope; Christopher M Callahan Journal: J Clin Epidemiol Date: 2004-10 Impact factor: 6.437
Authors: Krista L Lanctôt; Nathan Herrmann; Kenneth K Yau; Lyla R Khan; Barbara A Liu; Maysoon M LouLou; Thomas R Einarson Journal: CMAJ Date: 2003-09-16 Impact factor: 8.262
Authors: Gordon Wilcock; Ian Howe; Hilary Coles; Sean Lilienfeld; Luc Truyen; Young Zhu; Roger Bullock; Paul Kershaw Journal: Drugs Aging Date: 2003 Impact factor: 3.923
Authors: Zheng Kang Lum; Ma Serrie P Suministrado; N Venketasubramanian; M Kamran Ikram; Christopher Chen Journal: Singapore Med J Date: 2018-06-22 Impact factor: 1.858
Authors: Xiaobei Dong; Chi Chun Steve Tsang; Shirong Zhao; Jamie A Browning; Jim Y Wan; Marie A Chisholm-Burns; Christopher K Finch; Jack W Tsao; Lisa E Hines; Junling Wang Journal: Curr Med Res Opin Date: 2021-06-24 Impact factor: 2.705
Authors: Sandipan Bhattacharjee; Asad E Patanwala; Wei-Hsuan Lo-Ciganic; Daniel C Malone; Jeannie K Lee; Shannon M Knapp; Terri Warholak; William J Burke Journal: Alzheimers Dement (N Y) Date: 2019-07-10